## **Product** Data Sheet

## **JB062**

 Cat. No.:
 HY-152206

 CAS No.:
 2417988-00-0

 Molecular Formula:
 C<sub>19</sub>H<sub>17</sub>NO<sub>4</sub>

Molecular Weight: 323.34

Target: Myosin

Pathway: Cytoskeleton

**Storage:** Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	JB062 is a nonmuscle myosin inhibitor with IC <sub>50</sub> values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC50: 1.6 $\mu$ M (Skeletal muscle myosin), 5.4 $\mu$ M (Cardiac muscle myosin), and >100 $\mu$ M (Smooth muscle myosin II) $^{[1]}$
In Vitro	JB062 (compound 6b; 40 $\mu$ M; 24 h) inhibits cytokinesis in Cos-7 cells <sup>[1]</sup> . JB062 (COS-7 cells) has cytotoxic to human cancer cells but not normal cells with a CC <sub>10</sub> value of 36 $\mu$ M <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Smith JD, et, al. Isoform selectivities of novel 4-hydroxycoumarin imines as inhibitors of myosin II. Eur J Med Chem. 2022 Dec 12;247:115008.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA